

REFERENCES

A

Akbari CM, and LoGerfo FW (1999): Diabetes and peripheral artery disease. *J of Vasc Surg* 30:373–383.

Alberti, K and Zimmet, P (1998): Definition, Diagnosis and classification of diabetes mellitus and its complications. *Diabetc medicine*;15:539-553.

Alemzadeh R and Wyatt DT (2007): Diabetes Mellitus. In: Kliegman RM, ed. *Kliegman: Nelson Textbook of Pediatrics*. 18th ed. Philadelphia, Pa: Saunders; Chap 590.

Ali K, Yurdaer S, Gkhan O, Filiz B and Candoger Y (1995): Fibrinolytic activity in type II diabetes mellitus and the effect of glycemic control on fibrinolytic parameters. *Turk J Med Res*; 13(2): 74-77.

American Diabetes Association (2003): Peripheral arterial disease in people with diabetes. *Diabetes Care*; 26: 3333-3341.

American Diabetes Association (2005): Standards of medical care in diabetes. *Diabetes Care*; 28(Suppl 1): S4 – S36.

American Diabetes Association (2009): Standards of medical care in diabetes - 2008. *Diabetes Care*. 2009; 32:S13-S61.

American Journal of Health-system Pharmacy (2008): Cost effectiveness of Urokinase and alteplase for treatment of acute peripheral artery disease; August 1.2008 vol.65 no.15 1435-1442.

Anderson SL and Trujillo JM (2010): Association of pancreatitis with glucagon-like peptide-1 agonist use. *Ann Pharmacother*; 44(5): 904-909.

Andreas F, Ralph D, Agostino Jr, Russell P Tracy, Steven M and Haffner (2002): Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The insulin Resistance Atherosclerosis Study. *Diabetes*; 50: 1131-1137.

Arain FA, Khaleghi M, Bailey KR, Lahr BD, Rooke TW, Kullo IJ (2009): White blood cell count predicts all-cause mortality in patients with suspected peripheral arterial disease. *Am J Med.*; 122(9):874.e1-7.

Arlan R and Janet H S (2003): Type 2 Diabetes in Children and Adolescents: A Clinician's Guide to Diagnosis, Epidemiology, Pathogenesis, Prevention, and Treatment. American Diabetes Association, U.S.PP.1.

B

Bamashmus MA, Gunaid AA and Khandekar RB (2009): Diabetic retinopathy, visual impairment and ocular status among patients with diabetes mellitus in Yemen: a hospital-based study. *Indian J Ophthalmol*; 57(4):293-298.

Bastard J, Pieroni L, Hainque B (2000): Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. *Diabetes Metab. Res Rev*; 16: 192-201.

Bates D, Clark NG, Cook RI, et al. (2005): Position statement on

patient safety and medical system errors in diabetes and endocrinology. American College of Endocrinology and American Association of Clinical Endocrinologists. *Endocr Practt.*; 11:197-202.

Beckman JA, Creager MA and Libby P (2004): Diabetes and atherosclerosis: epidemiology, pathophysiology and management. *JAMA*; 287: 2570-2581.

Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J and Prager GW (2002): Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles. *News in Physiological Sciences*; 17(2): 56-61.

Bird CE, Criqui MH, Fronek A, Denenberg JO, Klauber MR and Langer RD (1999): Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing. *Vasc Med* 4:15–21.

Blann AD, Lip GY, Beevers DG and McCollum CN (1997): Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. *Thromb Haemost* 77:1077–1080.

Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH and Aronoff S (2010): Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. *Postgrad Med.*; 122(3):118-128.

Brenner ZR (2006): Management of hyperglycemic emergencies. *AACN Clin Issues*; 17(1):56-65.

Booth NA, Bachmann F, and Coleman RW, et al.(2006): Haemostasis and Thrombosis: Basic Principle and Clinical Practice.

Philadelphia, PA: Lippincott Williams and Wilkins; 17: 335-364.

C

Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D and Mulligan RC (1993): Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. *J Clin Invest* 92: 2746–2755.

Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D and Gerard RD (1997): Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. *Circulation* 96: 3180–3191.

Carreira M, Anarte MT, Ruiz De Adana MS, Félix Caballero F, Machado A, Domínguez-López M, González Molero I, Esteva De Antonio I, Valdés S, González-Romero S, Soriguer F (2010): Depression in type 1 diabetes mellitus and associated factors. *Med Clin (Barc)*. *Med Clin (Barc)*; 135(4): 151-5.

CDC; Center for Disease Control and Prevention (2005): Lower Extremity Disease Among Persons Aged >40 Years With and Without Diabetes --- United States, 1999—2002. *MMWR* 54(45); 1158-1160.

Chahin C, Rose B, Stuhlmiller S (2010): "Lower-Extremity Atherosclerotic Arterial Disease," *Medscape*. Available at <http://emedicine.medscape.com/article/423649-overview> (accessed July 2010).

- Chen Y, Budd RC, Kelm RJ, Sobel BE and Schneider DJ (2006):** Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. *Arterioscler Thromb Vasc Biol*; 1777-1783.
- Christ G, Hufnagl P, Kaun C, Mundigler G, Laufer G, Huber K, Wojta J and Binder BR (1997):** Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo. *Arterioscler Thromb Vasc Biol* 17: 723–730.
- Ciangura C (2010):** Physical activity in type 2 diabetes. *Rev Prat*; 60(4): 490-494.

D

- David S, Eriksson W, Boman K, and Maria k (2009):** Tissue plasminogen activator (t-PA) activity is a novel and early marker of asymptomatic LEAD in type II diabetes. *thrombosis research*; 123:701-706.
- David S, Jan W E, Kurt B and Maria K S (2009):** Tissue plasminogen activator (tpA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. *Thrombosis Research*; 123: 701-706.
- Davidson MB, Peters AL and Schriger DL (1995):** An alternative approach to the diagnosis of diabetes with a review of the literature. *Diabetes Care*; 8:1065-1071.
- Dean A, Dean J and Brenddle K (2004):** Epi-Info version 6.02 a word processing data base and statics program for epidemiology. Microcomputer.

Dellas C and Loskutoff DJ (2005): Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. *Thromb Haemost*; 93: 631-640.

Devaraj S, Cabo Chan AV and Jialal I (2002): α -Tocopherol Supplementation Decreases Plasminogen Activator Inhibitor-1 and P-Selectin Levels in Type 2 Diabetic Patients. *Diabetes Care*; 25(3): 524-529.

Dieter RS, Chu WW, Pacanowski JR, McBride PE, and Tanke TE (2002): The significance of lower extremity peripheral arterial disease. *Clin Cardiol*; 25:3-10.

Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C, Schneider JR, Luna AM, Martin G and McDermott MM (2002): Peripheral Artery Disease, Diabetes, and Reduced Lower Extremity Functioning. *Diabetes Care* 25(1): 113-120.

Dresslerová I and Vojáček J (2010): Diabetes mellitus and ischemic heart disease. *Vnitr Lek.*; 56(4):301-306.

Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ and Heiss G (1999): Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care*, 22:767-772.

E

Echeverry R, Wu J, Haile WB, Guzman J and Yepes M (2010): Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. *J Clin Invest*; 120(6):2194–2205.

- Edmonds ME, Morrison N, Laws JW and Watkins PJ (1982):** Medial arterial calcification and diabetic neuropathy. *Br Med J (Clin Res Ed)* 284:928–930.
- Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K and Pannekoek H (1991):** Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. *J Cell Biol* 115: 1773–1781.
- Eisenbarth GS, Polonsky KS and Buse JB (2008):** Type 1 Diabetes Mellitus. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. *Kronenberg: Williams Textbook of Endocrinology*. 11th ed. Philadelphia, Pa: Saunders Elsevier; Chap 31.
- Eliasson M, Evrin PE and Lundblad D (1994):** Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. *J Clin Epidemiol*, 47:513-524.
- Eliasson M, Evrin PE, Lundblad D, Asplund K and Rånby M (1993):** Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. *Fibrinolysis*, 7:316-323.
- Eliasson M, Jansson JH, Nilsson P and Asplund K (1997):** Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. *J Hypertens*, 15: 349-356.
- Eliasson M, Lindahl B, Lundberg V and Stegmayr B (2003):** Diabetes and obesity in northern Sweden - occurrence and risk factor for stroke and myocardial infarction. *Scand J Publ*

Health, 31(Suppl 61): 70-77.

Eliasson MCE, Jansson J-H, Lindah B and Stegmayr B (2003): High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study. Cardiovascular Diabetology, 2:19; doi: 10.1186/1475-2840-2-19 .

Elizabeth S, Keattiyotwattanakit, Michael W S, Josef C and Richey A S (2006): HbA_{1c} and peripheral Arterial Disease in Diabetes. Diabetes Care; 29: 877-882.

Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, and Marotti KR (1990): Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346: 74–76.

F

Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN and Haffner SM (1999): Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562–568.

Festa A, D'Agostino R., Jr., Tracy RP and Haffner SM (2002): Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 51:1131-1137.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL and Klijn JG (2000): The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. *Cancer Res* 60: 636–643.

Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H and Wu KK (2001): Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. *Arterioscler Thromb Vasc Biol* 21:611–617.

G

Gary NF and Sabovic Z (1998): Chromium Picolinate Supplementation for Diabetes Mellitus. *The Journal of Family Practice* 46: 83-86.

Goodney PP, Beck AW, Nagle J, Welch HG and Zwolak RM (2009): National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. *J Vasc Surg.*; 50(1):54-60.

Graves EJ (1992): National Center for Health Statistics: National Hospital Discharge Survey: Annual Summary, 1990. Hyattsville, MD, National Center for Health Statistics (Vital and Health Statistics Ser. 13, no. 112).

Green B (2010): Hypoglycaemia, sleep and the problems of cheap air travel. *Br J Nurs.*; 19(4):210.

Gregg EW, Beckles GL, Williamson DF, Leveille SG, Langlois JA,

- Engelgau MM and Narayan KM (2000):** Diabetes and physical disability among older U.S. adults. *Diabetes Care* 23:1272–1277.
- Gregg EW, Sorlie P, Paulose-Ram R, et al. (2004):** Prevalence of lower extremity disease in the U.S. adult population >40 years of age with and without diabetes: 1999—2000 National Health and Nutritional Examination Survey. *Diabetes Care*; 27:1591-1597.
- Guccione AA, Felson DT, Andersen JJ, Anthony JM, Zhang Y, Wilson PW, Kelly-Hayes M, Wolf PA, Kreger BE and Kannel WB (1994):** The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. *Am J Public Health* 84:351–358.
- Guralnik JM, Ferrucci L, Simonsick E, Salive ME and Wallace RB (1995):** Lower extremity function in persons over 70 years as a predictor of subsequent disability. *N Engl J Med* 332:556–561.
- Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA and Wallace RB (1994):** A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 49:M85–M94.
- Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ (2000):** Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. *Cancer Res* 60:

5839–5847.

H

Haffner SM, Stern MP, Hazuda HP, Mitchell BD and Patterson JK (1990): Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *JAMA*, 263:2893-2898.

Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME and Haffner SM (2002): Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. *Diabetes Care*, 25: 2016-2021.

Harris MI, Hadden WC, Knowler WC and Bennett PH (1987): Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. *Diabetes*; 36:523-534.

Hekman CM and Loskutoff DJ (1988): Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. *Arch Biochem Biophys* 262: 199–210.

Hough S, Slatopolsky E and Avioli LV (1983): Hormonal alterations in experimental diabetes: role of a primary disturbance in calcium homeostasis. *Calcif Tissue Int.*; 35(4-5):615-619.

J

- Jachen S and Werner AS (2006):** Autoimmune diagnosis in diabetes mellitus. Clin Chem Lab Med; 44(2): 133-137.
- Jaffery Z, Greenbaum AB, Siddiqui MF, Mahendraker N, Gupta V, Mekkala V, et al. (2009):** Predictors of mortality in patients with lower extremity peripheral arterial disease: 5-year follow-up. J Interv Cardiol.; 22(6):564-570.
- Jansson JH, Olofsson BO and Nilsson TK (1993):** Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation, 88:2030-2034.
- Jing X, Qiao R, Li M, Liu X, Kang D and Huang C (2010):** Gestational diabetes mellitus and the lifestyle and dietary structure of pregnant women: a case-control study. Wei Sheng Yan Jiu.; 39(2):209-11, 227.

K

- Kaistra T, Schrauwen K, Arts J and Emeis JJ (1994):** Regulation of endothelial cell t-PA synthesis and release. Int J Hematol; 59:
- Kaspar S (2010):** Veins and diabetes. Vnitr Lek.; 56(4):329-332.
- Kastl SP, Speidl WS, Kaan C, et al. (2006):** The component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-KappaB activation. J Thromb Haemost; 4:1790-1797.
- Kobayashi M (2002):** Diabetes mellitus and lifestyle. Intern Med.; 41(1): 63-64.

Kohler HP and Grant PJ (2000): Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med* 342: 1792–1801.

Komatsu K, Moriai N, Nakanome C, Satoh W, Sasaki S, Inomata M and Miura K (1983): A 10 year follow-up of diabetes in a rural area of Japan using the 50 g oral glucose tolerance test. *Tohoku J Exp Med. Dec; 141 Suppl:* 111-114.

Kooistra T, Schrauwen Y, Arts J and Emeis JJ (1994): Regulation of endothelial cell t-PA synthesis and release. *Int J Hematol;* 59:233-255.

Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC and Lindsay RS (2003): Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. *Diabetes Care*, 26:1745-1751.

Krebs M, Geiger M, Polak K, Vales A, Schmetterer L, Wagner OF, Waldhausl W, Binder BR and Roden M (2003): Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. *Thromb Haemost*, 90:422-428.

Kuritzky L, Epstein BJ and Lavernia F (2010): How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation. *Postgrad Med.*; 122(3):33-42.

- Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, Jern C and Boman K (2002):** Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. *Thromb Haemost*, 87:105-109.
- Lange de M, Snieder H, Ariens R, Andrew T, Grant PJ and Spector (2003):** The relation between insulin resistance and hemostasis: pleiotropic genes and common environment. *Twin Res*; 6: 1 – 10.
- Langer A, Freeman MR, Josse RG, Steiner G and Armstrong PW (1991):** Detection of silent myocardial ischemia in diabetes mellitus. *Am J Cardiology* 67:1073–1078.
- Larsson H, Berglund G, Lindgarde F and Ahren B (1998):** Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. *Diabetologia*; 41: 1124-1125.
- Lawrence D, Strandberg L, Grundstrom T, and Ny T (1989):** Purification of active human plasminogen activator inhibitor 1 from *Escherichia coli*. Comparison with natural and recombinant forms purified from eucaryotic cells. *Eur J Biochem* 186: 523–533.
- Lawrence DA and Loskutoff DJ (1986):** Inactivation of plasminogen activator inhibitor by oxidants. *Biochemistry* 25: 6351–6355.
- Leibson CL, Ransom JE, Olson W, Zimmerman BR, O'Fallon WM and Palumbo PJ (2004):** Peripheral arterial disease, diabetes,

and mortality. *Diabetes Care*; 27:2843-2849.

Lepercq J (2010): Gestational diabetes mellitus. *Rev Prat.*; 60(4):514-516.

Liu C-X, Li Y, Obermoeller-McCormick LM, Schwartz AL and Bu G (2001): The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. *J. Biol. Chem.* 276:28889-28896.

Lundblad D and Eliasson M (2003): Silent myocardial infarction in women with impaired glucose tolerance: The Northern Sweden MONICA study. *Cardiovasc Diabetol*, 2:9.

M

Malý R and Chovanec V (2010): Peripheral arterial disease and diabetes. *Vnitr Lek.*; 56(4):341-346.

Marubito JM, D'Agostino RB, Silbershatz H and Wilson WF (1997): Intermittent claudication: a risk profile from the Framingham Heart Study. *Circulation* 96: 44–49.

McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ and Bennett PH, et al. (1995): Which test for diagnosing diabetes? *Diabetes Care*; 18:1042-1044.

McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR and Knowler WC (1997): Diagnosing diabetes mellitus: do we need new criteria? *Diabetologia*; 40:247-2455.

McGill JB, Schneider DJ, Arfken CL, Lucore CL and Sobel BE (1994): Factors responsible for impaired fibrinolysis in obese

subjects and NIDDM patients. *Diabetes* 43:104–109.

Meigs J, Mittleman M, Nathan D, et al. (2000): Hyperinsulinaemia, hyperglycaemia and impaired hemostasis. The Framingham Offspring Study. *JAMA*; 283: 221-228.

Mihai G, Chung YC, Kariisa M, Raman SV, Simonetti OP and Rajagopalan S (2009): Initial feasibility of a multi-station high resolution three-dimensional dark blood angiography protocol for the assessment of peripheral arterial disease. *J Magn Reson Imaging.*; 30(4):785-793.

Morishita Erika, Hidesaku Asakura, Hiroshi Jakaji, Mansonri Saits, et al. (1996): Hypercoagulability and high lipoprotein (a) levels in patients with type II diabetes mellitus. *Atherosclerosis*; 120: 7-14.

Morsy MD, Hassan WN and Zalat SI (2010): Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats. *Diabetol Metab Syndr.*; 2(1):29.

Moussa ID, Jaff MR, Mehran R, Gray W, Dangas G, Lazic Z, et al. (2009): Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. *Catheter Cardiovasc Interv.*; 73(6):719-724.

N

Nakanishi S, Yamane K, Kamei N, Okubo M and Kohno N (2003): Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese americans. *Diabetes Care*, 26:

2754-2757.

Nar H, Bauer M, Stassen JM, Lang D, Gils A and Declerck PJ (2000): Plasminogen activator inhibitor-1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. *J Mol Biol* 297: 683–695.

Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, Heyman SN and Higazi A (2004): In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. *Blood*; 103(3):897–902.

Nathan DM (1993): Long-term complications of diabetes mellitus. *N Engl J Med* 328:1676–1685.

Nathaniel Clarks (2003): Preventive foot care in people with diabetes (position statement). American Diabetes Association. *Diabetes Care* 26(Suppl. 1): S78-S79.

National Diabetes Data Group (1979): Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes*; 28: 1039-1057.

Ny T, Elgh F and Lund B (1984): The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. *Proc. Natl. Acad. Sci. USA* 81:5355-5359.

P

Palumbo PJ and Melton LJ (1995): Peripheral Vascular Disease and Diabetes. www.t1da.org, T1da, Chapter 17: 401-408.

Pandolfi A, Cetrullo D, Polisbuck R, Alberta MM, Calafiore A, Pellegrini G, Vitocollona E, Capani F, et al. (2001): Plasminogen activator inhibitor type I is increased in the arterial wall of type 2 diabetic subjects. *Arterioscler Thrombo Vasc Biol*; 21: 1378-1382.

Pieber K, Hecceg M and Paternostro-Sluga T (2010): Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. *J Rehabil Med.*; 42(4):289-295.

Polavarapu R, Gongora MC, Yi H, Ranganthan S, Lawrence DA, Strickland D and Yepes M (2007): Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. *Blood*, 10(8): 3270-3278.

Premanath M and Raghunath M (2008): Ankle-brachial index by oscillometry: A very useful method to assess peripheral arterial disease in diabetes. *Int J Diab Dev Ctries*; 30(2): 97-101.

Pronina EA, Petraikina EE, Antsiferov MB, Duchareva OV, Petrone A, Buzzetti R and Pozzilli P (2008): A 10-year (1996-2005) prospective study of the incidence of Type 1 diabetes in Moscow in the age group 0-14 years. *Diabet Med.*;25(8):956-959.

Psyrogiannis A, Kyriazopoulou V and Vagenakis AG (1999): Medial arterial calcification is frequently found in patients with

microalbuminuria. *Angiology* 50:971–975.

Q

Quigley FG, Faris IB and, Duncan HJ (1991): A comparison of Doppler ankle pressures and skin perfusion pressure in subjects with and without diabetes. *Clin Physiol* 11:21–25.

R

Raffetto JD, Montgomery JE, Eberharolt RT, La Morte WW and Menzoian JO (2005): Differences in risk factors for lower extremity arterial occlusive disease. *J Am Coll Surg*; 201: 918-924.

Rafnsson SB, Deary IJ and Fowkes FG (2009): Peripheral arterial disease and cognitive function. *Vasc Med.*; 14(1):51-61.

Reed JF 3rd, Eid S, Edris B and Sumner AD (2009): Prevalence of peripheral artery disease varies significantly depending upon the method of calculating ankle brachial index. *Eur J Cardiovasc Prev Rehabil.*; 16(3):377-381.

Ridket PH, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH (2000): Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation*; 97: 425-428.

Robinson JG, Wang S, Smith BJ and Jacobson TA (2009): Meta-Analysis of the Relationship Between Non-High-Density

Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. Clinical Research: Coronary Disease Risk. J Am Coll Cardiol; 53: 316-322.

Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, Rifai N, Libby P, Creager MA and Ridker PM (1998): Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 18:1765–1770.

Ross R (1999): Atherosclerosis: an inflammatory disease. N Engl J Med 340:115S–126.

S

Saigo M, Hsue PY, and Waters DD (2004): Roles of thrombotic and fibrinolytic factors in acute coronary syndromes. Progress in cardiovascular diseases; 46:524-538.

Salame MY, Samani NJ, Masood I and deBono DP (2000): Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis, 152:19-28.

Santaguida PL, Balion C, Hunt D, et al. (2008): "Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose" Summary of Evidence Report/Technology Assessment, No. 128.

Serafín A, Molín J, Márquez M, Blasco E, Vidal E, Foradada L, Añor S, Rabanal RM, Fondevila D, Bosch F and Pumarola M (2010): Diabetic neuropathy: electrophysiological and

morphological study of peripheral nerve degeneration and regeneration in transgenic mice that express IFN β in beta cells. *Muscle Nerve*; 41(5):630-641.

Sheehan JJ and Tsirka SE(2005): "Fibrin-modifying serine proteases thrombin,tPA, and Plasmin in ischemic stroke: a review".*Glia*; 50(4): 340-350.

Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PGW, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell ER, Salvesen GS, Travis J, and Whisstock JC (2001): The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. *J Biol Chem* 276: 33293–33296.

Small M, Kluft C, MacCuish AC and Lowe GD (1989): Tissue plasminogen activator inhibition in diabetes mellitus. *Diabetes Care*; 12(9): 655-658.

Sobel BE (1996): Altered fibrinolysis and platelet function in the development of vascular complications of diabetes. *Curr Opin Endocrinol Diabet* 3:355–360.

Stamler J, Vaccaro O, Neaton JD and Wentworth D (1993): Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 16:434–444.

Stegenga M, Van der Crabben S, Levi M, et al. (2006): Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs

fibrinolysis in healthy individuals. *Diabetes*; 55: 1807-1812.

Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ and Parving HH (2002): Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. *Diabetes*, 51:1157-1165.

Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G and, Baron AD (1996): Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest*, 97: 2601-2610.

Steins M, Padro T, Li C, et al. (2000): Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. *Atherosclerosis*; 145: 173-180.

Stern MP (1995): Diabetes and cardiovascular disease. The "common soil" hypothesis. *Diabetes*, 44:369-374.

Stiles MC and Seaquist ER (2010): Cerebral structural and functional changes in type 1 diabetes. *Minerva Med.*; 101(2):105-114.

Sun Y, Wang JH and Qi XY (2005): The 1:3 matched case-control study of genetic mutations of gestational diabetes mellitus. *Chin Med Sci J.*; 20(2):141.

Suzanne M N, Elisa R and Mark G D (2006): Plasminogen activator system and vascular disease. *Current Vascular Pharmacology*; 4: 101-116.

Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Lijnen HR and Umemura K (2009): Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through

activation of lipoprotein receptor-related protein. *Blood*; 114(15): 3352-3358.

T

Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinhall L, Huhtasaari F and Hallmans G (1998): High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. *Circulation*, 98:2241-2247.

Thomas W J, Ansgar J P, Gunnar P and Frank-Chris S (2009): Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2. *Cardiovascular Diabetology*; 8: 24-28.

Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, et al. (2006): Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. *Am J Epidemiol.*; 163: 334-341.

U

UK Prospective Diabetes Study 6 (1990): Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. *Diabetes Res*,

13:1-11.

Unger J and Parkin CG (2010): Type 2 diabetes: an expanded view of pathophysiology and therapy. *Postgrad Med.*; 122(3):145-57.

V

Vaughan DE (2005): PAI-1 and atherothrombosis. *J Thromb Haemost*; 3:1879-1883.

Virtanen S and Knip M (2003): "Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age" . *Am J Clin Nutr*; 78 (6): 1053-1067.

W

WHO Expert Committee on Diabetes Mellitus (1980): second report. *World Health Organ Tech Rep Ser*; 646:1-80.

Wysham CH (2010): New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. *Postgrad Med.*; 122(3): 52-60.

Y

Yepes M, Loskutoff DJ, Lawrence DA, et al. (2006): Hemostasis and Thrombosis: Basic Principles and Clinical practice. Philadelphia, PA: Lippincott Williams and Wilkins; 23: 365-

380.

Yuan H, Vance KM, Junge CE, Geballe MT, Snyder JP, Hepler JR, Yepes M, Low C-M and Traynelis SF (2009): The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-d-aspartate Receptors. *The Journal of Biological Chemistry*, 284, 12862-12873.

Z

Zghal-Mokni I, Nacef L, Letaief I, Mahjoub S, Bouguila H, Blouza S, Jeddi A and Ayed S (2008): Ocular manifestations of diabetes: 285 cases. *Tunis Med.*; 86(11):1004-1007.

Zhang H, Li XY, Si YJ, Lu XL, Luo XS and Liu ZY (2010): Manifesta-tion of lower extremity atherosclerosis in diabetic patients with high ankle-brachial index. *Chin Med J (Engl)*. 5;123(7):890-894.